Lepicortinolo (Prednisolone)

Prednisolone binds to intracellular glucocorticoid receptors, forming a complex that moves into the cell nucleus. There it modulates gene expression by increasing anti‑inflammatory proteins and decreasing pro‑inflammatory cytokines, chemokines, and adhesion molecules, which collectively reduces inflammation and dampens immune responses.

The appropriate dose of Lepicortinolo is individualized by the prescribing clinician based on the specific condition, severity, patient weight, comorbidities, and response to therapy. No fixed dosing regimen is provided here; the prescriber will set the exact dosage and schedule.

The pregnancy category for prednisolone is listed as unknown, and safety data are limited. Use during pregnancy or lactation should only occur when the potential benefit justifies any potential risk, and it must be discussed with a qualified healthcare professional.

To request Lepicortinolo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lepicortinolo delivers prednisolone, a medium‑potency glucocorticoid. Compared with higher‑potency agents such as dexamethasone, prednisolone generally has a shorter half‑life and may require more frequent dosing, but it offers a well‑characterized safety profile and is often preferred for moderate inflammatory conditions.

Lepicortinolo tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister or container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Lepicortinolo is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional. Administration timing (e.g., with food) may be advised by the prescriber to reduce gastrointestinal irritation.

Serious risks include severe infections due to immune suppression, adrenal insufficiency on abrupt discontinuation, osteoporosis with long‑term use, and gastrointestinal bleeding or ulceration, especially when combined with NSAIDs. Patients should be monitored closely for signs of these complications.

Lepicortinolo is contraindicated in patients with known hypersensitivity to prednisolone or any excipients, those with systemic fungal infections, and individuals receiving live vaccines without appropriate medical guidance. Caution is also advised for patients with uncontrolled diabetes, severe hypertension, or active peptic ulcer disease.